High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: The TromsØ study

Haematologica

Volumn 96, Issue 8, 2011, Pages 1189-1194

  Hald, Erin M ^a,b   Braækkan, Sigrid K ^a   Mathiesen, Ellisiv B ^a   NjØlstad, Inger ^a   Wilsgaard, Tom ^a   Brox, Jan ^a,b   Hansen, John Bjarne ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

C reactive protein; Cardiovascular disease; Prospective study; Risk factors; Venous thromboembolism

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; VENOUS THROMBOEMBOLISM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; VENOUS THROMBOEMBOLISM;

EID: 79961033795     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.034991     Document Type: Article

References (45)

1. Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. J Thromb Haemost. 2008;6(11):1851-1857
2. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15): 1435-1441
3. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370(9601): 1773-1779
4. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol. 2005;162 (10):975-982
5. Libby P, Ridker PM, Hansson GK. Inflam - mation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-2138
6. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111(12):1805-1812
7. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-140
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-979
9. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):483-495
10. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36 (6):1316-1329
11. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511
12. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697-706
13. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;21(1): 23-29
14. Sacks GP, Seyani L, Lavery S, Trew G. Maternal C-reactive protein levels are raised at 4 weeks gestation. Hum Reprod. 2004;19(4):1025-1030
15. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. Jama. 1999;282(22):2131-2135
16. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61(9):824-833
17. Rumley A, Emberson JR, Wannamethee SG, Lennon L, Whincup PH, Lowe GD. Effects of older age on fibrin D-dimer, Creactive protein, and other hemostatic and inflammatory variables in men aged 60-79 years. J Thromb Haemost. 2006;4(5):982-987
18. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82(2):513-520
19. Luxembourg B, Schmitt J, Humpich M, Glowatzki M, Dressler D, Seifried E, et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost. 2009;102(4): 668-675
20. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost. 2009; 102(4):615-619
21. Quist-Paulsen P, Naess IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica. 2010;95(1): 119-125
22. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113(8):636-642
23. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol. 2010;30(8):1672-1678
24. Zee RY, Hegener HH, Cook NR, Ridker PM. C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis. J Thromb Haemost. 2004;2(8):1240-1243
25. Vormittag R, Funk M, Mannhalter C, Schonauer V, Vukovich T, Minar E, et al. Creactive protein 3' UTR +1444C>T polymorphism in patients with spontaneous venous thromboembolism. Atherosclerosis. 2006;188(2):406-411
26. Lippi G, Favaloro EJ, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med. 2010;48(12): 1693-1701
27. Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, Hillege HL, et al. Microalbuminuria and risk of venous thromboembolism. JAMA. 2009;301(17): 1790-1797
28. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81(5):680-683
29. Kanz R, Vukovich T, Vormittag R, Dunkler D, Ay C, Thaler J, et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost. 2010;9(1):57-63
30. Vormittag R, Vukovich T, Schonauer V, Lehr S, Minar E, Bialonczyk C, et al. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost. 2005;93 (3):488-493
31. Jezovnik MK, Poredos P. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Int Angiol. 2010;29(3):226-231
32. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost. 2004;2(4):619-622.
33. van Aken BE, den Heijer M, Bos GM, van Deventer SJ, Reitsma PH. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost. 2000;83(4):536-539
34. Christiansen SC, Naess IA, Cannegieter SC, Hammerstrom J, Rosendaal FR, Reitsma PH. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med. 2006; 3(8):e334.
35. Devaraj S, Rogers J, Jialal I. Statins and biomarkers of inflammation. Curr Atheroscler Rep. 2007;9(1):33-41
36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Green - wich). 2007;9(8):622-628
37. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation. 2002;106(8):1024-1028
38. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replace - ment Study. Ann Intern Med. 2000; 132 (9):689-696
39. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161(11):1405-1410
40. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851-1861
41. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93-102.
42. Poredos P, Jezovnik MK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol. 2007;26(4):306-311
43. Arslan F, Pasterkamp G, de Kleijn DP. Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective. Circ Res. 2008;103(4):334-336
44. Hong C, Zhu F, Du D, Pilgram TK, Sicard GA, Bae KT. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis. 2005;183(1):169-174
45. Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost. 2007;5(Suppl 1):270-275